Does denosumab offer survival benefits? —Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small-cell lung cancer (NSCLC). Denosumab is a humanized monoclonal antibody to RANK ligand used to prevent skeletal-related events of bone metastases in solid tumors. We are reporting the clinical outcomes in o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yenong, Afzal, Muhammad Zubair, Shirai, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411139/
https://www.ncbi.nlm.nih.gov/pubmed/34527308
http://dx.doi.org/10.21037/jtd-21-150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411139/
https://www.ncbi.nlm.nih.gov/pubmed/34527308
http://dx.doi.org/10.21037/jtd-21-150

Ejemplares similares